Serum gp100 as an Independent Prognostic Biomarker in Early-Stage Uveal Melanoma
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.6.80 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2025. Verfasst von Manuel F Bande und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ocular Oncology Unit, Department of Ophthalmology, Complexo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms, Biomarkers, Tumor, gp100 Melanoma Antigen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the prognostic significance of serum gp100 levels in patients with uveal melanoma (UM) without detectable metastases at diagnosis.
Methods
This prospective study included 37 patients with UM and no clinical evidence of metastasis at baseline. Serum gp100 concentration was quantified using a commercial ELISA kit. Tumors were molecularly profiled and categorized into high- or low-risk classes. Patients were stratified based on the median gp100 concentration (1.23 ng/mL). Survival analysis was performed using Kaplan-Meier estimates, and multivariate logistic regression was used to identify independent predictors of metastasis.
Results
During a mean follow-up of 24.6 months, 14 patients (37.8%) developed metastases. Patients with baseline gp100 >1.23 ng/mL had significantly shorter metastasis-free survival (P < 0.001). Receiver operating characteristic (ROC) analysis yielded an area under the curve of 0.89, with a cutoff of 1.387 ng/mL, achieving 85.7% sensitivity and 82.6% specificity. In multivariate analysis, serum gp100 remained an independent predictor of metastasis (odds ratio = 3849.9; 95% confidence interval, 9.66-1,534,206; P = 0.007), regardless of molecular classification. No significant correlations were found between gp100 and clinical or genetic parameters.
Conclusions
Elevated serum gp100 is an independent biomarker of early metastatic risk in UM, even in the absence of clinical or genetic high-risk features. ELISA-based measurement of gp100 may support noninvasive stratification and personalized surveillance strategies in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ocular Oncology Unit, Department of Ophthalmology, Complexo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain.
- Department of Surgery and Medical-Surgical Specialties, University of Santiago de Compostela, Santiago de Compostela, Spain.
- Grupo Obesidómica, Instituto de Investigación Sanitaria de Santiago (IDIS), CHUS/SERGAS, Santiago de Compostela, Spain.
- Fundación Pública Galega de Medicina Xenómica, CHUS/SERGAS, Santiago de Compostela, Spain.
Zitieren
APA
Bande, M. F., Piñeiro, C., Lago-Baameiro, N., Silva-Rodríguez, P., Pardo, M., & Blanco-Teijeiro, M. J. (2025). Serum gp100 as an Independent Prognostic Biomarker in Early-Stage Uveal Melanoma. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.6.80
Vancouver
Bande MF, Piñeiro C, Lago-Baameiro N, Silva-Rodríguez P, Pardo M, Blanco-Teijeiro MJ. Serum gp100 as an Independent Prognostic Biomarker in Early-Stage Uveal Melanoma. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.6.80
BibTeX
@article{Bande2025,
author = {Bande, Manuel F and Piñeiro, Carmen and Lago-Baameiro, Nerea and Silva-Rodríguez, Paula and Pardo, María and Blanco-Teijeiro, María José},
title = {Serum gp100 as an Independent Prognostic Biomarker in Early-Stage Uveal Melanoma},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.6.80}
}
EUVIMED